Phase Ib study of KL-A167 injection in the treatment of relapsed or refractory extranodal NK/T-cell lymphoma (nasal type) and B-cell non-Hodgkin's lymphoma
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Tagitanlimab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- 17 Jan 2025 New trial record